560 related articles for article (PubMed ID: 21888887)
21. Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Pompili L; Leonetti C; Biroccio A; Salvati E
J Exp Clin Cancer Res; 2017 Dec; 36(1):189. PubMed ID: 29273061
[TBL] [Abstract][Full Text] [Related]
22. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
23. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
24. Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.
Gocha ARS; Harris J; Groden J
Mutat Res; 2013; 743-744():142-150. PubMed ID: 23219603
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.
Waitkus MS; Erman EN; Reitman ZJ; Ashley DM
Neuro Oncol; 2024 Jun; 26(6):1012-1024. PubMed ID: 38285162
[TBL] [Abstract][Full Text] [Related]
26. Telomere length heterogeneity in ALT cells is maintained by PML-dependent localization of the BTR complex to telomeres.
Loe TK; Li JSZ; Zhang Y; Azeroglu B; Boddy MN; Denchi EL
Genes Dev; 2020 May; 34(9-10):650-662. PubMed ID: 32217664
[TBL] [Abstract][Full Text] [Related]
27. Caenorhabditis elegans POT-2 telomere protein represses a mode of alternative lengthening of telomeres with normal telomere lengths.
Cheng C; Shtessel L; Brady MM; Ahmed S
Proc Natl Acad Sci U S A; 2012 May; 109(20):7805-10. PubMed ID: 22547822
[TBL] [Abstract][Full Text] [Related]
28. Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R.
Fujiwara M; Kamma H; Wu W; Yano Y; Homma S; Satoh H
Int J Oncol; 2006 Aug; 29(2):445-51. PubMed ID: 16820888
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.
Perrem K; Colgin LM; Neumann AA; Yeager TR; Reddel RR
Mol Cell Biol; 2001 Jun; 21(12):3862-75. PubMed ID: 11359895
[TBL] [Abstract][Full Text] [Related]
30. A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT).
Jeitany M; Pineda JR; Liu Q; Porreca RM; Hoffschir F; Desmaze C; Silvestre DC; Mailliet P; Junier MP; Londoño-Vallejo A; Ségal-Bendirdjian E; Chneiweiss H; Boussin FD
Int J Cancer; 2015 Apr; 136(7):1546-58. PubMed ID: 25175359
[TBL] [Abstract][Full Text] [Related]
31. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
32. Alternative Lengthening of Telomeres Mediated by Mitotic DNA Synthesis Engages Break-Induced Replication Processes.
Min J; Wright WE; Shay JW
Mol Cell Biol; 2017 Oct; 37(20):. PubMed ID: 28760773
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma.
Lee YK; Park NH; Lee H
Int J Gynecol Cancer; 2012 Mar; 22(3):434-41. PubMed ID: 22266933
[TBL] [Abstract][Full Text] [Related]
34. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.
Slatter T; Gifford-Garner J; Wiles A; Tan X; Chen YJ; MacFarlane M; Sullivan M; Royds J; Hung N
Am J Pathol; 2010 Dec; 177(6):2694-700. PubMed ID: 21037079
[TBL] [Abstract][Full Text] [Related]
35. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
36. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
Macha SJ; Koneru B; Burrow TA; Zhu C; Savitski D; Rahman RL; Ronaghan CA; Nance J; McCoy K; Eslinger C; Reynolds CP
Cancer Res; 2022 Sep; 82(18):3345-3358. PubMed ID: 35947641
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis.
Queisser A; Heeg S; Thaler M; von Werder A; Opitz OG
Cancer Genet; 2013 Nov; 206(11):374-86. PubMed ID: 24331919
[TBL] [Abstract][Full Text] [Related]
38. Telomere length alterations and ATRX/DAXX loss in pituitary adenomas.
Heaphy CM; Bi WL; Coy S; Davis C; Gallia GL; Santagata S; Rodriguez FJ
Mod Pathol; 2020 Aug; 33(8):1475-1481. PubMed ID: 32203094
[TBL] [Abstract][Full Text] [Related]
39. Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis.
Lawlor RT; Veronese N; Pea A; Nottegar A; Smith L; Pilati C; Demurtas J; Fassan M; Cheng L; Luchini C
BMC Cancer; 2019 Mar; 19(1):232. PubMed ID: 30871494
[TBL] [Abstract][Full Text] [Related]
40. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection?
Nittis T; Guittat L; Stewart SA
Biochimie; 2008 Jan; 90(1):5-12. PubMed ID: 17935854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
